• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Proscia, DoMore Diagnostics Partner on Personalized Treatment Decisions For Colorectal Cancer Patients

by Syed Hamza Sohail 08/30/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer (CRC) patients.
  • The collaboration paves the way for integrating artificial intelligence AI-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care.

AI-Driven Outcome Prediction Models for Colorectal Cancer Patients

CRC is the third most common and second most deadly cancer worldwide. While adjuvant chemotherapy may be provided after primary surgery to prevent the disease from recurring, predicting when it will lead to overtreatment can be challenging. Up to 90% of patients with stage II and stage III cases do not realize any benefit from adjuvant chemotherapy and only suffer side effects.

The partnership paves the way for delivering an integrated solution that combines DoMore Diagnostics’ CE-IVDD marked Histotype Px® Colorectal* digital biomarker with Proscia’s CE-IVDR marked Concentriq® Dx** enterprise pathology platform. Data previously published in The Lancet and Lancet Oncology demonstrated that Histotype Px Colorectal can successfully predict outcomes for stage II and stage III CRC patients. Combined with tumor and lymph node status, the test report provides information about patients’ risk profile and 5-year cancer-specific survival to inform the decision to use adjuvant chemotherapy.

“We have proven that Histotype Px Colorectal can offer valuable insight to guide personalized treatment decisions and help improve patient outcomes,” said Torbjørn Furuseth, MD, CEO and Co-founder of DoMore Diagnostics. “We must now continue to integrate the algorithm into pathologists’ routine operations for it to make the greatest impact. As leading laboratories are increasingly turning to Proscia, our partnership paves the way for accelerating its adoption.”

Concentriq Dx is an enterprise pathology platform that drives primary diagnostic workflows for reference laboratories, hospitals, and health systems of all sizes. It offers a compelling user experience that allows pathologists to quickly transition away from the microscope and work with speed and ease. An open platform, Concentriq Dx is designed to integrate AI applications from Proscia, Proscia’s customers, and leading third parties, including DoMore Diagnostics, into routine workflows so that laboratories can realize the full promise of pathology’s computational future at scale.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |